• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Singulair (montelukast sodium) Tablet, Film Coated

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- April 2008


The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.

Summary View

Sections Modified


  • Postmarketing Experience
    • Psychiatric Disorders
      • Anxiousness
      • Suicidal thinking and behavior (including suicide)


  • Less common side effects that have happened with Singulair include:
    • Behavior and Mood related changes
      • Feeling anxious
      • Suicidal thoughts and actions (including suicide)...